A combination of two commonly prescribed medicines may offer the first real chance of stopping early-stage Peyronie’s disease before it causes permanent damage, according to a new study that is drawing attention among urologists and fibrosis researchers worldwide.

The findings, published in The Journal of Sexual Medicine, suggest that combining phosphodiesterase type 5 (PDE5) inhibitors such as Sildenafil and Tadalafil with selective oestrogen receptor modulators (SERMs) like Tamoxifen could slow and, in some cases, even halt the progression of the disease in men diagnosed during the early inflammatory phase.

Peyronie’s disease, often hidden behind silence and embarrassment, occurs when scar tissue develops inside the penis. Over time, that scar tissue can pull the penis into a curve during erection, causing pain, shortness, difficulty during sex and severe emotional stress. Experts estimate that nearly one in ten men may experience the condition at some point in life, although many never seek treatment because of stigma or fear.

Anglia Ruskin University and University College London Hospital jointly conducted the latest research. Professor David Ralph, one of Britain's leading specialists in male sexual health, led the clinical work.

The study tracked 133 men diagnosed with acute Peyronie’s disease. Patients received a combination of PDE5 inhibitors and tamoxifen for three months. Their outcomes were compared with a smaller control group receiving standard care, including vitamin E or no active treatment. Surgery was not part of the treatment plan.

The results were striking. Around 43 percent of men receiving the drug combination showed improvements in penile curvature, compared with just 15 percent in the standard care group.

Pain reduction was even more dramatic. At the beginning of treatment, nearly 65 per cent of men in the combination group reported painful erections. Three months later, that percentage had dropped to just 1.5%. In the control group, pain rates dropped from 50 per cent to 27 per cent.

Researchers say the findings matter because there are currently no approved oral medicines proven to stop the disease in its early stage. Many patients are simply told to wait until the condition “stabilises” before being considered for injections or surgery. For many men, that waiting period can feel brutal.

Doctors involved in the study believe the new approach may change that.

Professor Selim Cellek said the clinical results validated years of laboratory research aimed at understanding fibrosis, the abnormal scarring process behind Peyronie’s disease.

“Positive findings from this pilot clinical study validate our drug-screening approach in the lab,” Professor Cellek said.

“It shows how repurposing well-known medicines can accelerate progress in areas of unmet clinical need.”

Inside ARU’s fibrosis laboratory, researchers spent years examining how ordinary cells called fibroblasts transform into aggressive scar-forming cells known as myofibroblasts. Those cells act almost like microscopic construction workers that never stop building. Instead of healing tissue normally, they keep laying down thick scar material that bends and stiffens the penis.

In a painstaking screening program, the team tested 1,953 FDA-approved medicines, one by one, to identify compounds capable of interrupting that harmful process. PDE5 inhibitors and SERMs repeatedly stood out in Petri dishes and microscope studies. When combined, the effect appeared stronger than either drug alone.

Researchers say that kind of “drug repurposing” is becoming increasingly important in modern medicine because developing brand-new drugs can take over a decade and cost billions. Repurposed medicines already have known safety profiles, making clinical adoption potentially faster if larger trials confirm the findings.

Professor Ralph said the study demonstrated how years of basic science research were now beginning to translate into real-world patient benefit.

“This paper confirms the basic science research with regards to halting the progression of Peyronie’s disease,” he said.

“His work has now been put into clinical practice where this paper shows that when tamoxifen and a PDE5 inhibitor are combined, there is statistically less progression of the disease and improvement in curvature compared to the control arm.”

Experts not directly linked to the study have also been exploring anti-fibrotic strategies in recent years. Researchers in Europe and the United States have investigated collagen-blocking therapies, shockwave treatment and injectable enzymes aimed at breaking down scar tissue. However, many of these treatments remain expensive, invasive or limited to laterstages of disease.

What makes the new findings especially intriguing is their focus on early intervention. Scientists increasingly believe Peyronie’s disease behaves much like other fibrotic disorders affecting organs such as the lungs or liver. Once scar tissue hardens and matures, reversing damage becomes far more difficult.

That means timing may be everything.

For ordinary patients, the emotional impact can be devastating. Studies published over the past decade have linked Peyronie’s disease with depression, relationship breakdowns, anxiety, and loss of self-esteem. Many men delay seeking medical help for months or even years because they assume the condition is untreatable or too embarrassing to discuss.

The researchers caution that the current findings come from a pilot clinical study, and larger prospective trials are still needed before the therapy becomes routine practice. Still, the results have generated cautious optimism because they hint at something medicine has long struggled to achieve — stopping the disease before permanent scarring takes hold.

If future studies prove the benefits, doctors might finally have an easy oral treatment that can not only manage symptoms but also change the progression of Peyronie’s disease.